Hemodynamic effect of ethacrynic acid in patients with refractory acute left ventricular failure

The management of acute heart failure and diuretic therapy

One million patients are hospitalized each year with acute decompensated heart failure, and up to 20% of these patients are rehospitalized within a month after the acute presentation. Acute heart failure (AHF) accounts for 50,000 deaths annually and is the most frequent reason for hospital admissions in the United States. This article reviews the therapeutic options and the results of recent clinical trials in the treatment of AHF. Most patients can be effectively managed by use of diuretic agents or diuretics in combinations with nitrates, IV nitroglycerin, IV nitroprusside, and possibly IV nesiritide. Ultrafiltration is a promising technique that can be very helpful in the resistant patient. However, given the ease of initiation of diuretic therapy, it is unlikely that ultrafiltration would supplant diuretic use in acutely symptomatic patients. Patients in acute distress with AHF almost invariably respond to diuretics or a vasodilator combined with diuretic therapy. The loop diuretics are the most effective diuretics and thus most frequently used agents in treating AHF. Currently, there are 4 loop diuretics in the US market: furosemide, bumetanide, torsemide, and ethacrynic acid. IV furosemide and ethacrynic acid have a prompt venous dilatory effect, consequently decrease left ventricular filling pressure and immediately relieve symptoms of pulmonary congestion, before a diuresis can occur. Furosemide is more often used than ethacrynic acid due to its reduced ototoxic potential. However, ethacrynic acid should be used in sulfa-sensitive patients because ethacrynic acid is the only loop diuretic, which does not contain a sulfa moiety.

The clinical pharmacology of ethacrynic acid

Ethacrynic acid (Edecrin) is a loop diuretic that produces a prompt and profound diuresis. The primary action of ethacrynic acid is the inhibition of the activity of the Na⁺-K⁺-2Cl⁻ symporter in the thick ascending limb of the loop of Henle. The onset of action is usually within 30 minutes after an oral dose and within 5 minutes after an intravenous injection. After oral administration, peak diuretic effect occurs in about 2 hours and the effect lasts about 6-8 hours. After intravenous administration, peak diuretic effect occurs within 30 minutes and the diuretic effect is virtually completed in 2-4 hours. The bioavailability of ethacrynic acid approximates 100%, with maximal blood level between 40 and 92 minutes. The elimination half-life has been reported to be less than 1 hour, but highly variable (average 30 minutes with a range of 12-160 minutes). Intravenous ethacrynic acid has a prompt venous dilatory effect and immediately relieves symptoms of pulmonary congestion, before a diuresis can occur. Ethacrynic acid is effective in all types of edema whether there is clinical acidosis, alkalosis, or electrolyte imbalance. Most side effects of ethacrynic acid can be attributed to its effectiveness (volume depletion); however, it may cause metabolic alkalosis that is preventable by KCl replacement. Ethacrynic acid has ototoxic effect that occasionally results in temporally or permanent deafness. Despite limitations, ethacrynic acid has been employed in the treatment of congestive heart failure and other edematous states, especially in patients allergic to sulfa-containing drugs because all the other loop diuretics have a sulfa moiety.

Haemodynamics and renal function following injection of bumetanide

Haemodynamics and renal function have been investigated in 12 patients with valvular heart disease before and after injection of 2 mg bumetanide in the right heart catheter. There were no significant changes in oxygen consumption, arteriovenous oxygen difference, cardiac index, heart beats per minute, stroke volume or right and left ventricular stroke work 35 min after the injection, whereas pulmonary and systemic arteriolar resistance showed a slight but insignificant reduction. Mean pulmonary capillary venous pressure, left ventricular end-diatolic pressure, mean pulmonary arterial pressure and mean pressure in the right atrium were highly significantly reduced after injection, systolic left ventricular pressure showing a significant but slight decrease. The creatinine and urea clearances increased considerably during the first 50 min after injection of bumetanide, but diminished during the second period to levels somewhat lower than the initial values. There was also a marked increase in the clearance of sodium potassium, calcium, magnisium and phosphate. It is concluded that bumetanide is a very potent diuretic which changes haemodynamic parameters towards normal values.

Effect of furosemide on hemodynamics and lung water in acute pulmonary edema secondary to myocardial infarction

Hemodynamic studies were carried out in 19 patients with left ventricular failure complicating acute myocardial infarction. Fourteen patients were studied before and after the intravenous administration of 0.5 mg/kg of furosemide, and five patients served as a control group. Serial measurements included intracardiac pressures, cardiac output and lung water by a double isotope technique. A significant reduction was noted in right atrial (P less than 0.005), pulmonary arterial (P less than 0.0005) and pulmonary wedge pressures (P less than 0.0005) after administration of furosemide. Only the change in right atrial pressure was significantly different from that in the control group (P less than 0.05). Lung water was not changed in 4 patients studied 2 hours after administration of furosemide but was significantly changed in the remaining 10 patients studied 4 to 24 hours after furosemide (P = 0.0001). This change was also significantly different from values in the control group (P less than 0.05). The patients with no reduction in excess lung water also had a smaller reduction in pulmonary wedge pressure and a lower pretreatment stroke work index than the other patients. The mobilization of excess lung water in patients with acute myocardial infarction complicated by left ventricular failure has several features. Despite a prompt diuresis, the reduction in lung water is delayed for at least several hours after the administration of furosemide and may be related to the degree of left ventricular dysfunction. Venodilation may be a major result of treatment with furosemide.

The acute hemodynamic effects of ethacrynic acid and furosemide in patients with chronic postcapillary pulmonary hypertension

The acute hemodynamic effects of either ethacrynic acid or furosemide were studied in 27 patients who underwent diagnostic right and transseptal left heart catheterization. Twenth-three patients had postcapillary pulmonary hypertension secondary to isolated or predominant mitral stenosis. Of these, 21 patients were in New York Heart Association functional class III, and one each in class II and IV. In the remaining four patients pulmonary artery pressures were normal. Two patients had aortic stenosis and one each coronary artery disease and nonobstructive cardiomyopathy. All four patients were in class II. Cardiac index, pressures, and pulmonary blood volume (PBV) were measured in the control state and 20, 40, and 60 min after diuretic administration. Pulmonary extravascular fluid volume (PEV) was measured in the control state and at 60 min post drug infusion. A similar hemodynamic response was observed for each drug. Significant reductions in pulmonary artery and left atrial mean pressures, cardiac index, and plasma volume occurred over the one hour observation period and were accompanied by a significant duiresis. However, despite recutions in central pressures and blood flow, PBV, ev, and PEV/PBV remained unchanged, as did systemic arterial pressure. Since 23 of the subjects had postcapillary pulmonary hypertension it is postulated that the failure of PBV to decrease significantly despite significant decreases in pulmonary artery mean pressure is related to altered pressure volume characteristics in the pulmonary vascular bed in which the lung is operating on a steep portion of its pressure volume curve. The failure of the PEV to decrease supports the concept that the pulmonary extravascular space is relatively resistant to early decreases in pulmonary capillary pressure induced acutely. The failure of the pulmonary extravascular fluid volume to decrease despite a fall in plasma volume and pressures corresponds to the well recognized delay in resolution of radiologic evidence of pulmonary congestion.

Diuretics: mechanism of action and clinical application

Despite the bewildering number of diuretics available to the physician, these drugs can be divided into 4 main groups, characterised by their site of action on sodium reabsorption in the kidney. Drugs acting on the ascending limb of the loop of Henle have a powerful but short acting diuretic effect; they include frusemide, ethacrynic acid and bumetanide. The benzothiadiazines and related compounds have a moderate diuretic action spread over a longer period, whilst the potassium-sparing diuretics, triamterene, amiloride and spironolactone, have only a weak diuretic effect but a marked ability to diminish urinary potassium excretion. The fourth group is made up of miscellaneous substances which function as vasodilator or osmotic agents. The pathogenesis of oedema formation in heart failure is outlined and a logical approach to treatment suggested. Duiretics are being increasingly used in the treatment of non-oedematous states, in particular hypertension, diabetes insipidus and hypercalciuria; their exact role in pregnancy and acute renal failure remains controversial. Side-effects can be related to their effect on electrolyte excretion and include hypokalaemia, hyponatraemia, hyperkalaemia and hyperuricaemia. The incidence of disturbed carbohydrate tolerance in previously normal individuals is low. Other less common side-effects are also discussed.

Heart failure complicating acute myocardial infarction

Congestive heart failure (CHF) occurs in about one half of all patients with acute myocardial infarction and is a manifestation of acute alterations in left ventricular function. In the present study CHF is defined on clinical grounds, according to the presence and extent of bilateral pulmonary rales. An accompanying S 3 ventricular gallop was heard in 58% of our patients with heart failure initially, but it disappeared eventually in the majority. Dilatation of pulmonary veins and blurring of pulmonary vascular markings are useful roentgenographic signs which reflect elevations in left heart filling pressure. At times the earliest indicators of heart failure, these findings appear in general to be less sensitive than the physical examination in diagnosing CHF. Although stroke volume is decreased with CHF, cardiac index is generally maintained by increased heart rate. Left ventricular minute work and stroke work are significantly decreased, while left ventricular end-diastolic pressure is significantly increased, in patients with CHF complicating acute myocardial infarction. Arterial hypoxemia is common and the degree of arteriovenous shunting is roughly proportional to the elevation of left ventricular filling pressure. The mortality of patients with CHF is approximately three times that of patients with acute myocardial infarction and no complications. Diuretic therapy is safe and effective. Attention is called to the probability that the use of digitalis preparations in the early hours following myocardial infarction is hazardous. Furthermore, hemodynamic benefit from digitalization in the early postinfarction period remains unproven.